Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 10585 record(s)

Req # A-2023-000143

Adverse Drug Reactions (ADRs) for Morphine. Report numbers: 001028749, E2B_06119778, E2B_06169209, E2B_06176648. ADR for Hydromorphone. Report number: 001028758.

Organization: Health Canada

61 page(s)
March 2024

Req # A-2023-000212

Adverse Drug Reactions (ADRs). Report numbers: E2B_06042674, E2B_06191755, 001027968, E2B_06179338, 001028307, 001039442, 001029988, 001030424, E2B_06152243.

Organization: Health Canada

287 page(s)
March 2024

Req # A-2023-000379

Adverse Drug Reactions (ADRs). Report numbers: E2B_06260941, E2B_06232105.

Organization: Health Canada

70 page(s)
March 2024

Req # A-2023-000452

Adverse Drug Reactions (ADRs) for PANTOPRAZOLE SODIUM. Report numbers: E2B_06305106, E2B_06329467, E2B_06320786. ADRs for MESALAZINE. Report numbers: E2B_06319865, E2B_06304517, 001036580, 001037459.

Organization: Health Canada

808 page(s)
March 2024

Req # A-2023-000722

Adverse Drug Reactions (ADRs). Report numbers: E2B_06176930, 001028202, E2B_05043142, E2B_06132086, E2B_06151402, E2B_04700794, E2B_02294819, E2B_06162162, E2B_04948393 E2B_05337204.

Organization: Health Canada

239 page(s)
March 2024

Req # A-2023-000835

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-104454-497.

Organization: Health Canada

37 page(s)
March 2024

Req # A-2023-000867

Adverse Drug Reactions (ADRs). Report numbers: E2B_04483418, 000975144, 000977212, 001010854, E2B_04779384, E2B_04800606, E2B_04877938, 000993771, 000996067 000993460.

Organization: Health Canada

119 page(s)
March 2024

Req # A-2023-000873

Adverse Drug Reactions (ADRs). Report numbers: 001020619, E2B_06058464, E2B_05992299 , E2B_05973308, E2B_05992323, E2B_05992299, E2B_05972707, E2B_05998320, E2B_05974945, 001019223.

Organization: Health Canada

75 page(s)
March 2024

Req # A-2023-000908

Adverse Drug Reaction (ADR) for Tecta. Report number: E2B_06483597. ADRs for Mesalazine. Report numbers: E2B_06501204, E2B_06486442, E2B_06479972, E2B_06510119, E2B_06482978, E2B_06479977, E2B_06522595. ADRs for VYVANSE. Report numbers: 001049057, 001051263.

Organization: Health Canada

129 page(s)
March 2024

Req # A-2023-000914

Adverse Drug Reactions (ADRs). Report numbers: 001047973, 001043279.

Organization: Health Canada

15 page(s)
March 2024
Date modified: